Active SLE PR-SLE P
N = 15 N = 15
Duration of SLE (years) 9.25 (5.75 – 12.5) 25.6 (19.1 – 35.4) < 0.001
Remission time (years) n/a 16.9 (12.1 – 20.6) n/a
SLICC 2012 SLE classification criteria items 7 (6 – 9) 7 (6 – 8) 0.50
Acute cutaneous lupus 12 (80) 10 (66.7) 0.63
Chronic cutaneous lupus 1 (6.7) 0 (0) 0.55
Nasal or oral ulcers 6 (40) 9 (60) 0.39
Alopecia 2 (13.3) 4 (26.7) 0.62
Synovitis 13 (86.7) 13 (86.7) 0.92
Serositis 2 (13.3) 3 (20) 0.82
Renal 6 (40) 4 (26.7) 0.50
Neurologic 0 (0) 3 (20) 0.18
Autoimmune Hemolytic Anemia 1 (6.7) 1 (6.7) 0.96
Leuko-lymphopenia 11 (73.3) 12 (80) 0.18
Thrombocytopenia 3 (20) 3 (20) 0.87
Positive ANA 14 (93.3) 15 (100) 0.55
Positive anti-dsDNA 15 (100) 11 (73.3) 0.04
Positive anti-Smith 4 (26.7) 0 (0) 0.01
Antiphospholipid antibodies 8 (53.3) 6 (40) 0.69
Hypocomplementemia 12 (80) 9 (60) 0.38
Positive Coombs test 4 (26.7) 0 (0) 0.06
SLEDAI 2K 8 (6 – 16) 0 (0 – 2) < 0.001
Arthritis 7 (46.6) 0 (0) 0.001
Hematuria 4 (26.6) 0 (0) 0.01
Proteinuria 8 (53.3) 0 (0) < 0.001
Pyuria 5 (33.3) 0 (0) < 0.01
Low complement 11 (73.3) 7 (46.6) 0.23
Increased anti-dsDNA titers 12 (80.0) 5 (33.3) 0.02
Fever 1 (6.6) 0 (0) 0.45
Serological SLEDAI 2K items
C3 (mg/dL) 81 (67 – 128) 113 (79 – 128) 0.24
Low C3 (%) 10 (66.7) 4 (26.7) 0.07
C4 (mg/dL) 11 (8 – 20) 19 (12 – 30) 0.10
Low C4 (%) 10 (66.7) 7 (46.7) 0.42
anti-dsDNA (UI/mL) 225.1 (20.2 – 586.9) 7.2 (4.5 – 12.8) < 0.01
SLICC/ACR DI 0 (0 – 1) 1 (0 – 1) 0.10
Secondary APS 2 (13.3) 6 (40) 0.36
Treatment 15 (100) 0 (0) n/a
Prednisone 7 (46.7) n/a n/a
Dose (mg) 15 (6.25 – 27.5) n/a n/a
Immunosupressor 13 (86.6) n/a n/a
Azathioprine 5 (33.3) n/a n/a
Methotrexate 4 (26.7) n/a n/a
Mycophenolate mofetil 4 (26.7) n/a n/a
Antimalarial 10 (73.3) n/a n/a
n/a: not applicable. ANA: antinuclear antibodies. SLEDAI: SLE Disease Activity Index. SLICC: Systemic Lupus International Collaborating Clinics. SLICC / ACR DI: Systemic Lupus International Collaborating Clinics / American College of Rheumatology Damage Index. APS: Antiphospholipid Syndrome. Results for quantitative variables are shown in Median with Interquartile Range, and Kruskal Wallis test was used to perform comparisons between groups. For quantitative variables measured only in two groups, Mann Whitney U test was used to perform comparisons between both groups. The qualitative variables are presented in frequencies, using Chi squared test to compare between groups. Only the SLEDAI 2K items that were present in at least one study subject from either SLE group are shown. Prednisone dose is shown from the 7 Active SLE patients who had it prescribed. n/a: not applicable. ANA: antinuclear antibodies. SLEDAI: SLE Disease Activity Index. SLICC: Systemic Lupus International Collaborating Clinics. SLICC / ACR DI: Systemic Lupus International Collaborating Clinics / American College of Rheumatology Damage Index. APS: Antiphospholipid Syndrome. Results for quantitative variables are shown in Median with Interquartile Range, and Kruskal Wallis test was used to perform comparisons between groups. For quantitative variables measured only in two groups, Mann Whitney U test was used to perform comparisons between both groups. The qualitative variables are presented in frequencies, using Chi squared test to compare between groups. Only the SLEDAI 2K items that were present in at least one study subject from either SLE group are shown. Prednisone dose is shown from the 7 Active SLE patients who had it prescribed. n/a: not applicable. ANA: antinuclear antibodies. SLEDAI: SLE Disease Activity Index. SLICC: Systemic Lupus International Collaborating Clinics. SLICC / ACR DI: Systemic Lupus International Collaborating Clinics / American College of Rheumatology Damage Index. APS: Antiphospholipid Syndrome. Results for quantitative variables are shown in Median with Interquartile Range, and Kruskal Wallis test was used to perform comparisons between groups. For quantitative variables measured only in two groups, Mann Whitney U test was used to perform comparisons between both groups. The qualitative variables are presented in frequencies, using Chi squared test to compare between groups. Only the SLEDAI 2K items that were present in at least one study subject from either SLE group are shown. Prednisone dose is shown from the 7 Active SLE patients who had it prescribed. n/a: not applicable. ANA: antinuclear antibodies. SLEDAI: SLE Disease Activity Index. SLICC: Systemic Lupus International Collaborating Clinics. SLICC / ACR DI: Systemic Lupus International Collaborating Clinics / American College of Rheumatology Damage Index. APS: Antiphospholipid Syndrome. Results for quantitative variables are shown in Median with Interquartile Range, and Kruskal Wallis test was used to perform comparisons between groups. For quantitative variables measured only in two groups, Mann Whitney U test was used to perform comparisons between both groups. The qualitative variables are presented in frequencies, using Chi squared test to compare between groups. Only the SLEDAI 2K items that were present in at least one study subject from either SLE group are shown. Prednisone dose is shown from the 7 Active SLE patients who had it prescribed.